C4 Therapeutics, Inc. — Form 8-K
Filed September 25, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 45/100
What the filing says
C4 Therapeutics reported that the 75 μg cemsidomide dose level in combination with elranatamab (ELREXFIO) was declared safe by the safety review committee in an ongoing Phase 1b trial in relapsed/refractory multiple myeloma. The trial is advancing to dose expansion (75 μg) and dose escalation (100 μg) cohorts, with all cohort data expected mid-2027. Biomarker data from the first two Phase 1b patients showed T-cell activation and prevention of T-cell exhaustion.
Why this rating
Positive clinical progression on lead program supporting label strategy. Phase 1b safety clearance is routine trial milestone; meaningful but not transformational for ~$100M market-cap biotech.
See more from September 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.